CLINICAL TRIALS PROFILE FOR TENALISIB
✉ Email this page to a colleague
Clinical Trials for Tenalisib
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT03471351 ↗ | Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL | Terminated | Rhizen Pharmaceuticals SA | Phase 1 | To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) for Tenalisib in combination with Pembrolizumab in patients with cHL. |
NCT03711578 ↗ | Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL) | Completed | Rhizen Pharmaceuticals SA | Phase 2 | To assess the anti-tumor activity and safety of Tenalisib in patients with relapsed/refractory indolent Non-Hodgkin's Lymphoma (iNHL), |
NCT03711604 ↗ | Compassionate Use Study of Tenalisib (RP6530) | Enrolling by invitation | Rhizen Pharmaceuticals SA | Phase 1/Phase 2 | Tenalisib has been evaluated as an investigational new drug in number of early clinical studies in patients with relapsed/refractory hematological malignancies and demonstrated acceptable safety and promising efficacy in these patients. Since these advanced relapsed/refractory patients have limited therapeutic options, it is reasonable to continue Tenalisib in responding patients post completion of their participation in previous clinical studies. |
NCT03770000 ↗ | Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma | Completed | Rhizen Pharmaceuticals SA | Phase 1/Phase 2 | To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) of Tenalisib in combination with Romidepsin in patients with R/R T-cell lymphoma. |
NCT04204057 ↗ | Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) | Completed | Rhizen Pharmaceuticals SA | Phase 2 | The trial is a Phase II, open label, Simon's two stage study design to evaluate the efficacy and safety of Tenalisib in patients with CLL who have relapsed or are refractory after at least one prior therapy. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Tenalisib
Condition Name
Clinical Trial Locations for Tenalisib
Trials by Country
Clinical Trial Progress for Tenalisib
Clinical Trial Phase
Clinical Trial Sponsors for Tenalisib
Sponsor Name